The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.45
High: 1.45
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
1st Oct 201911:00 amRNSPrice Monitoring Extension
1st Oct 20199:05 amRNSSecond Price Monitoring Extn
1st Oct 20199:00 amRNSPrice Monitoring Extension
1st Oct 20197:01 amRNSStoneChecker USA Market Introduction
1st Oct 20197:00 amRNSIssue of Equity
30th Sep 201911:05 amRNSSecond Price Monitoring Extn
30th Sep 201911:00 amRNSPrice Monitoring Extension
27th Sep 20197:00 amRNSFDA Clearance to Market for StoneChecker Software
16th Sep 20199:34 amRNSReplacement - Half Yearly Report to 30 June 2019
16th Sep 20197:00 amRNSHalf-year Report
4th Sep 20197:00 amRNSGrant Award
6th Aug 20197:00 amRNSCompletion of Placing and Conversion of Loan Notes
5th Aug 20192:05 pmRNSSecond Price Monitoring Extn
5th Aug 20192:00 pmRNSPrice Monitoring Extension
9th Jul 20197:00 amRNSUpdate on Gadolinium Free Imaging Project
26th Jun 20197:00 amRNSPlacing
24th Jun 20192:52 pmRNSHolding(s) in Company
20th Jun 20194:40 pmRNSSecond Price Monitoring Extn
20th Jun 20194:35 pmRNSPrice Monitoring Extension
12th Jun 20197:00 amRNSBusiness Development Agreement with CorTechs Labs
6th Jun 201911:49 amRNSResult of AGM
29th May 201911:51 amRNSIssue of Convertible Loan Notes - Correction
29th May 20198:22 amRNSIssue of Convertible Loan Notes
17th May 201912:00 pmRNSExtension of Loan Notes Redemption Date
9th May 20191:30 pmRNSNotice of AGM
9th May 201912:13 pmRNSHolding(s) in Company
30th Apr 201912:00 pmRNSPublication of Annual Report
2nd Apr 20197:00 amRNSImaging Biometrics Update
11th Mar 20197:00 amRNSIssue of Convertible Loan Notes
8th Feb 201910:29 amRNSBusiness Update
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.